The company behind an imaging agent meant to identify prostate cancer said it received FDA approval on Thursday for use in patients with suspected metastasis or recurrence.
Share this article
Share this article
LOS ANGELES, May 25, 2021 /PRNewswire/ In recognition of Military Appreciation Month, the Prostate Cancer Foundation (PCF) announced today its new $2.5 million commitment to launch the Drew Foundation Precision Oncology Center of Excellence in collaboration with the University of California, San Francisco (UCSF) and the San Francisco VA Health Care System (SFVAHCS) to deliver best-in-class precision oncology treatments to Veterans with prostate cancer. PCF is committed to continuing to expand our partnership with the VA to advance cutting-edge research and care for Veterans with prostate cancer, said Jonathan W. Simons, MD, PCF president and CEO. Partnering with the University of California, San Francisco brings top expertise to our precision oncology efforts serving our nation s Veterans. UCSF researchers co-developed the latest FDA-approved PSMA-PET scan which zeroes in on prostate cancer that has spread through the body so it can be b
National implementation shared-care trial to benefit men with prostate cancer miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
The Prostate Cancer Foundation of NZ has reacted positively to the new initiatives announced by the government to improve screening of women in Aotearoa for cervical and breast cancers
Source:Â Prostate Cancer Foundation
The Prostate Cancer Foundation of NZ has reacted positively to the new initiatives announced by the government to improve screening of women in Aotearoa for cervical and breast cancers. However, the charity believes that the initiatives do highlight a disparity in approaches towards different cancers by successive governments and in the health system.
âIt is heartening to see the Government’s willingness to listen and react to the new science around how best to protect the population from the devastating effects of cancerâ says Peter Dickens, Chief Executive of the Prostate Cancer Foundation.Â
âThe move to screening for the HPV virus in women shows that they are willing to adopt the gold standard practice already in place in other countries. However, in the case of prostate cancer, the government’s approach is informed by outdated and superseded views that we believe significantly understate the benefit of screening for t